If you were to ask me where Wall Street reform stands right now, I’d give it an incomplete. Well, actually I’d give it a C. There are some decent measures in the Senate bill, even a couple transformative ones, but overall some gaps in the regulatory structure remain, and the same financial oligarchs will have the ability to overrun the system, if in different ways.

Ryan Grim reports that a bipartisan group of Senators is backing an amendment that will restore the Grayson-Paul “audit the fed” language to the Senate Financial Reform bill after Chris Dodd gutted it.

The FDA says the reimportation of drugs into this country from Canada and other developed nations would be “difficult to implement” and “resource-intensive,” and would involve “significant safety concerns.” Republicans have already cost Americans $20 billion or so just in the past couple years obstructing reimportation, which should be the law of the land already. You’d think the president would find an FDA commissioner who’d fix this.

Opponents of the Employee Free Choice Act in Congress made their Big Lie into a bill Wednesday, when Republicans John DeMint (S.C.) and Mike Enzi (Wyo.) introduced the so-called Secret Ballot Protection Act.

Before we go further, let’s clear up the bill’s false implication right now:

The Employee Free Choice Act would not—repeat after me—would not, take away the secret ballot National Labor Relations Board (NLRB) election process if workers seeking to form a union wanted to use it.